Zhaozhong Ding

Zhaozhong Ding (丁照中) is co-founder and chairman of Yangli Pharma (扬厉医药), with more than 30 years of drug R&D and management experience, per Qiming Venture Partners' coverage of the company. He was publicly representing the company when its Series B (a nine-figure RMB round led by Qiming) closed in late 2025, and again in March 2026 when its pipeline asset VB19055's IND was accepted by the FDA — which he called "an important milestone in Yangli's global R&D." Beyond his role at Yangli, elsewhere's corpus doesn't cover his earlier career or background.